領益智造(002600.SZ):可行權的股票期權共148.916萬份
格隆匯9月16日丨領益智造(002600.SZ)公佈,2018年股票期權與限制性股票激勵計劃預留授予期權簡稱:領益JLC2;期權代碼:037831。
此次激勵計劃預留授予符合此次行權條件的254名激勵對象在第二個行權期可行權的股票期權數量共計148.916萬份,行權價格為6.03元/股。
此次行權採用自主行權模式。
公司此次激勵計劃預留授予部分共四個行權期,根據可交易日及行權手續辦理情況,實際可行權期限為2021年9月17日至2022年9月9日,截至公吿日,已在中國證券登記結算有限責任公司深圳分公司辦理完成相關手續。
此次可行權股票期權若全部行權,公司股份仍具備上市條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.